This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
The impact of thrombosis on probabilities of death and disease progression in polycythemia vera: a multistate transition analysis of 1,545 patients
Blood Cancer Journal Open Access 15 December 2023
-
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
Annals of Hematology Open Access 04 October 2023
-
Systemic inflammatory indices for predicting prognosis of myelofibrosis
Scientific Reports Open Access 02 August 2023
Access options
Subscribe to this journal
Receive 12 print issues and online access
$259.00 per year
only $21.58 per issue
Rent or buy this article
Prices vary by article type
from$1.95
to$39.95
Prices may be subject to local taxes which are calculated during checkout
References
Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007; 110: 1092–1097.
Mesa RA, Verstovsek S, Cervantes F, Barosi G, Reilly JT, Dupriez B et al. Primary myelofibrosis (PMF), post polycythemia vera myelofibrosis (post-PV MF), post essential thrombocythemia myelofibrosis (post-ET MF), blast phase PMF (PMF-BP): consensus on terminology by the international working group for myelofibrosis research and treatment (IWG-MRT). Leuk Res 2007; 31: 737–740.
Thiele J, Kvasnicka HM, Facchetti F, Franco V, van der Walt J, Orazi A . European consensus on grading bone marrow fibrosis and assessment of cellularity. Haematologica 2005; 90: 1128–1132.
Manoharan A, Horsley R, Pitney WR . The reticulin content of bone marrow in acute leukaemia in adults. Br J Haematol 1979; 43: 185–190.
Cervantes F, Alvarez-Larrán A, Talarn C, Gómez M, Montserrat E . Myelofibrosis with myeloid metaplasia following essential thrombocythemia: actuarial probability, presenting characteristics and evolution in a series of 195 patients. Br J Haematol 2002; 118: 786–790.
Author information
Authors and Affiliations
Consortia
Corresponding author
Rights and permissions
About this article
Cite this article
Barosi, G., Mesa, R., Thiele, J. et al. Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the international working group for myelofibrosis research and treatment. Leukemia 22, 437–438 (2008). https://doi.org/10.1038/sj.leu.2404914
Published:
Issue Date:
DOI: https://doi.org/10.1038/sj.leu.2404914
This article is cited by
-
Young patients with myelofibrosis have distinct clinicomolecular features, favorable prognosis, and commonly exhibit inflammatory comorbidities
Annals of Hematology (2024)
-
Real-world clinical characteristics of post-essential thrombocythemia and post-polycythemia vera myelofibrosis
Annals of Hematology (2024)
-
Systemic inflammatory indices for predicting prognosis of myelofibrosis
Scientific Reports (2023)
-
Real-world analysis of ruxolitinib in myelofibrosis: interim results focusing on patients who were naïve to JAK inhibitor therapy treated within the JAKoMo non-interventional, phase IV trial
Annals of Hematology (2023)
-
JAK2V617F variant allele frequency, non-driver mutations, single-nucleotide variants and polycythemia vera outcome
Journal of Cancer Research and Clinical Oncology (2023)